With approval of monoclonal antibody-based radiopharmaceuticalsproceeding faster in Europe than in the U.S., market prospectsfor equipment using these targeted nuclear medicine agents arealso more immediate in that region. Care Wise Medical Products of
With approval of monoclonal antibody-based radiopharmaceuticalsproceeding faster in Europe than in the U.S., market prospectsfor equipment using these targeted nuclear medicine agents arealso more immediate in that region.
Care Wise Medical Products of Morgan Hill, CA, developer ofthe OncoProbe intraoperative nuclear probe, is lining up Europeandistributors for its product, according to Louis A. McKellar,executive vice president.
OncoProbe's primary use is in guiding surgeons to ovarian andcolorectal tumors. The company expects to benefit from Cytogen'sprogress over the last two months in gaining national approvalsfor its colorectal cancer monoclonal agent, OncoScint CR103, inGermany, Luxembourg, Holland and Great Britain.
The Princeton, NJ, biotechnology firm also plans to apply shortlyfor ovarian cancer imaging applications of OncoScint in Europe(SCAN 11/20/91).
In addition to Cytogen, monoclonal antibody agents for colorectaland other applications have been developed by Behring Werke, asubsidiary of Frankfurt-based Hoechst AG. These agents have receivedfavorable reports from European clinicians, McKellar said.
Although OncoProbe is purchased by surgeons, nuclear medicinephysicians are often closely involved in recommending the productand training other physicians and nurses in its use with monoclonalimaging agents, McKellar said. The patient is scanned with a nuclearmedicine camera prior to surgery to localize tumors, so nuclearmedicine physicians actually see a rise in their workload withuse of the probe.
"Nuclear medicine physicians are usually very helpfulin saying which surgeons we should talk to first. They have the(monoclonal) antibodies. When they understand our probe, theyusually push the use of it with imaging agents and the use ofthe gamma camera beforehand. We make their product look better,"McKellar said.
Care Wise has hired an agent to arrange national distributorsin Europe. The company has initiated talks with parties in theU.K., Italy and Germany, he said.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Enhanced Mobile CT System with High-Resolution Photon-Counting Technology
July 15th 2024Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.